ES3001444T3 - 1-isopropyl-3-methyl-8- (pyridin-3-yl) -1, 3-dihydro-2h-imidazo [4, 5-c] cinnolin-2-one as selective modulators of ataxia telangiectasia mutated (atm) kinase and uses thereof - Google Patents

1-isopropyl-3-methyl-8- (pyridin-3-yl) -1, 3-dihydro-2h-imidazo [4, 5-c] cinnolin-2-one as selective modulators of ataxia telangiectasia mutated (atm) kinase and uses thereof Download PDF

Info

Publication number
ES3001444T3
ES3001444T3 ES19860219T ES19860219T ES3001444T3 ES 3001444 T3 ES3001444 T3 ES 3001444T3 ES 19860219 T ES19860219 T ES 19860219T ES 19860219 T ES19860219 T ES 19860219T ES 3001444 T3 ES3001444 T3 ES 3001444T3
Authority
ES
Spain
Prior art keywords
methyl
compound
imidazo
pharmaceutically acceptable
isopropyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES19860219T
Other languages
English (en)
Spanish (es)
Inventor
Ding Zhou
Ziqiang Cheng
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Suzhou Zanrong Pharma Ltd
Original Assignee
Suzhou Zanrong Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Suzhou Zanrong Pharma Ltd filed Critical Suzhou Zanrong Pharma Ltd
Application granted granted Critical
Publication of ES3001444T3 publication Critical patent/ES3001444T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D519/00Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50Pyridazines; Hydrogenated pyridazines
    • A61K31/5025Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ES19860219T 2018-09-14 2019-09-16 1-isopropyl-3-methyl-8- (pyridin-3-yl) -1, 3-dihydro-2h-imidazo [4, 5-c] cinnolin-2-one as selective modulators of ataxia telangiectasia mutated (atm) kinase and uses thereof Active ES3001444T3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2018105675 2018-09-14
PCT/CN2019/105951 WO2020052688A1 (en) 2018-09-14 2019-09-16 1-ISOPROPYL-3-METHYL-8- (PYRIDIN-3-YL) -1, 3-DIHYDRO-2H-IMIDAZO [4, 5-c] CINNOLIN-2-ONE AS SELECTIVE MODULATORS OF ATAXIA TELANGIECTASIA MUTATED (ATM) KINASE AND USES THEREOF

Publications (1)

Publication Number Publication Date
ES3001444T3 true ES3001444T3 (en) 2025-03-05

Family

ID=69777300

Family Applications (1)

Application Number Title Priority Date Filing Date
ES19860219T Active ES3001444T3 (en) 2018-09-14 2019-09-16 1-isopropyl-3-methyl-8- (pyridin-3-yl) -1, 3-dihydro-2h-imidazo [4, 5-c] cinnolin-2-one as selective modulators of ataxia telangiectasia mutated (atm) kinase and uses thereof

Country Status (9)

Country Link
US (1) US12226414B2 (https=)
EP (2) EP4516318A3 (https=)
JP (2) JP7436465B2 (https=)
KR (1) KR102813324B1 (https=)
CN (2) CN112752758B (https=)
AU (1) AU2019339006B2 (https=)
CA (1) CA3111994A1 (https=)
ES (1) ES3001444T3 (https=)
WO (1) WO2020052688A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7436465B2 (ja) * 2018-09-14 2024-02-21 スゾウ、ザンロン、ファーマ、リミテッド 毛細血管拡張性運動失調症変異(ATM)キナーゼの選択的調節物質としての1-イソプロピル-3-メチル-8-(ピリジン-3-イル)-1,3-ジヒドロ-2H-イミダゾ[4,5-c]シンノリン-2-オンおよびその使用
AU2021433713A1 (en) * 2021-03-17 2023-09-28 Suzhou Zanrong Pharma Limited Selective modulators of ataxia telangiectasia mutated (atm) kinase and uses thereof
CN115304598B (zh) * 2021-08-25 2024-05-31 石药集团中奇制药技术(石家庄)有限公司 一种杂环类化合物及其制备方法和用途
GB202114704D0 (en) * 2021-10-14 2021-12-01 Univ Birmingham ATM inhibition
MX2024009184A (es) * 2022-01-26 2024-07-30 Chia Tai Tianqing Pharmaceutical Group Co Ltd Compuesto que contiene grupo hidrazino.
WO2025183591A1 (ru) * 2024-02-29 2025-09-04 Федеральное государственное унитарное предприятие "Всероссийский научно-исследовательский институт автоматики им. Н.Л. Духова" (ФГУП "ВНИИА") Производные 2н-[1,4]оксазино- и 2h-[1, 4]тиазино[3,2-c]хинолин-3(4h)-онов в качестве ингибиторов атм и dna-pk киназ

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9624482D0 (en) 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
BR9707495A (pt) 1996-02-13 1999-07-27 Zeneca Ltd Derivado de quinazolina processo para a preparação do mesmo composição farmacêutica e processo para a produç o de um efeito antiangiogênico e/ou de redução de permeabilidade vascular em um animal de sangue quente
US6291455B1 (en) 1996-03-05 2001-09-18 Zeneca Limited 4-anilinoquinazoline derivatives
GB9718972D0 (en) 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
NO2714752T3 (https=) * 2014-05-08 2018-04-21
GB201516504D0 (en) * 2015-09-17 2015-11-04 Astrazeneca Ab Imadazo(4,5-c)quinolin-2-one Compounds and their use in treating cancer
GB201519406D0 (en) 2015-11-03 2015-12-16 Astrazeneca Ab Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer
GB201519568D0 (en) * 2015-11-05 2015-12-23 Astrazeneca Ab Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer
US20190099421A1 (en) * 2016-03-21 2019-04-04 Astrazeneca Ab Cinnolin-4-amine compounds and their use in treating cancer
GB201608227D0 (en) * 2016-05-11 2016-06-22 Astrazeneca Ab Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer
WO2019057757A1 (en) * 2017-09-20 2019-03-28 Astrazeneca Ab 1,3-DIHYDROIMIDAZO [4,5-C] CINNOLIN-2-ONE COMPOUNDS AND THEIR USE IN THE TREATMENT OF CANCER
JP7436465B2 (ja) * 2018-09-14 2024-02-21 スゾウ、ザンロン、ファーマ、リミテッド 毛細血管拡張性運動失調症変異(ATM)キナーゼの選択的調節物質としての1-イソプロピル-3-メチル-8-(ピリジン-3-イル)-1,3-ジヒドロ-2H-イミダゾ[4,5-c]シンノリン-2-オンおよびその使用

Also Published As

Publication number Publication date
AU2019339006A1 (en) 2021-04-01
JP7706585B2 (ja) 2025-07-11
JP2024054247A (ja) 2024-04-16
EP3849984A1 (en) 2021-07-21
WO2020052688A1 (en) 2020-03-19
EP4516318A3 (en) 2025-04-30
CN115636833A (zh) 2023-01-24
CA3111994A1 (en) 2020-03-19
EP3849984A4 (en) 2022-06-01
CN115636833B (zh) 2024-11-29
AU2019339006B2 (en) 2024-03-14
US12226414B2 (en) 2025-02-18
KR102813324B1 (ko) 2025-05-26
EP3849984B1 (en) 2024-11-13
US20220047595A1 (en) 2022-02-17
JP2022500428A (ja) 2022-01-04
CN112752758A (zh) 2021-05-04
CN112752758B (zh) 2023-05-23
EP4516318A2 (en) 2025-03-05
JP7436465B2 (ja) 2024-02-21
EP3849984C0 (en) 2024-11-13
KR20210061337A (ko) 2021-05-27

Similar Documents

Publication Publication Date Title
ES3001444T3 (en) 1-isopropyl-3-methyl-8- (pyridin-3-yl) -1, 3-dihydro-2h-imidazo [4, 5-c] cinnolin-2-one as selective modulators of ataxia telangiectasia mutated (atm) kinase and uses thereof
KR102889933B1 (ko) 항종양제로서의 퀴나졸린 유도체
ES2670416T3 (es) Compuestos de imidazo[4,5-c]quinolin-2-ona y su uso en el tratamiento de cáncer
CN114867726A (zh) Kras g12c突变体的小分子抑制剂
AU2022202886B2 (en) Quinazoline Compounds, Preparation Method, Use, and Pharmaceutical Composition Thereof
KR20230068412A (ko) Cbp/ep300 브로모도메인 억제제로서의 헤테로시클릭 화합물
WO2023036156A1 (zh) Dna-pk选择性抑制剂及其制备方法和用途
JP2024545235A (ja) 複素芳香族化合物、その製造方法及び使用
CA3175102A1 (en) Erbb receptor inhibitors as anti-tumor agents
WO2023109751A1 (zh) 嘧啶或吡啶类衍生物及其医药用途
JP7833477B2 (ja) 血管拡張性失調症変異(atm)キナーゼの選択的モジュレーターおよびその使用
WO2026037231A1 (zh) 蛋白激酶抑制剂